News Headlines

  1. Charles River And BioTech Social Inc. Pursue Crowdfunding Partnership 7/31/2025

    Charles River Laboratories International, Inc. and BioTech Social Inc. (BSI) today announced the exploration of a potential client-centric collaboration to enable Charles River Incubator (CIP) and Accelerator (CAP) Program participants to access the BioTech Funding Portal, an investment crowdfunding platform for life science companies.

  2. Psyence BioMed's Strategic Collaboration With PsyLabs Yields Breakthrough In High-Purity Ibogaine Production 7/31/2025

    Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) is pleased to announce that its strategic partner, PsyLabs – a leader in the production of purified psychedelic compounds – has successfully produced a GMP-aligned Ibogaine Total Alkaloid extract.

  3. PL BioScience Announces Major Site Expansion 7/31/2025

    PL BioScience GmbH, a German life science company specializing in the production and development of Human Platelet Lysate (HPL) for cell expansion, today announced a significant expansion of company headquarters and future manufacturing capabilities to meet the rapidly growing global demand for safe, animal-free cell culture supplements.

  4. ESTEVE CDMO Acquires Regis Technologies, Expanding U.S. Presence And Capabilities 7/31/2025

    ESTEVE acquires Regis Technologies, a United States-based Contract Development and Manufacturing Organization (CDMO), headquartered in Chicago.

  5. European Commission Approves CAR-T Therapy With Lentiviral Vectors Manufactured By AGC Biologics 7/31/2025

    Following news on July 21 that the European Commission has granted marketing authorization for AUCATZYL (obecabtagene autoleucel – obe-cel), AGC Biologics’ Milan site achieved its 10th product approval from the European Medicines Agency or the U.S. Food and Drug Administration.

  6. Dr. Falk Pharma And Allianthera (Suzhou) Biopharmaceuticals Forge Strategic Partnership For Novel AhR Agonist Development 7/30/2025

    Dr. Falk Pharma GmbH and Allianthera (Suzhou) Biopharmaceuticals Co., Ltd. Announce Strategic Partnership to Develop a Novel AhR Agonist for the Treatment of Moderate to Severe Ulcerative Colitis

  7. Sandoz Signs Non-Binding Term Sheet With Evotec SE To Acquire Its Just-Evotec Biologics In-House Development And Manufacturing Capabilities In Toulouse, France 7/30/2025

    Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, announced today that it has signed a non-binding term sheet with Evotec SE.

  8. AGC Biologics' Heidelberg Site Supplies Drug Substance For Phase II Studies Of Valneva's Tetravalent Shigella Vaccine Candidate 7/29/2025

    AGC Biologics, your friendly CDMO expert, today announced a development and manufacturing services agreement with specialty vaccine company Valneva SE to supply drug substance for an investigational four-valent Shigella bioconjugate vaccine at the CDMO’s Heidelberg facility.

  9. Bio Usawa Biotechnology And Sartorius Stedim Biotech Forge Partnership To Pioneer Biopharmaceutical Manufacturing In Africa 7/29/2025

    Bio Usawa Biotechnology, Ltd. (Bio Usawa), a leading African biotechnology firm, and Sartorius Stedim Biotech, a global partner of biopharmaceutical manufacturing, have announced a partnership to accelerate Africa’s biopharmaceutical industry and address the continent’s urgent, dual health burdens in infectious and non-communicable diseases.

  10. WuXi Biologics Singapore CRDMO Hub Advances With The Launch Of Modular Drug Product Facility Fabrication 7/29/2025

    WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced construction has begun for a new modular Drug Product (DP) facility, which will become part of the company's CRDMO hub in Singapore.